In approving Sandoz Inc.’s Erelzi (etanercept-szzs), FDA found itself caught between wanting to label the biosimilar as closely as possible to the reference product, Amgen Inc.’s Enbrel, while also recognizing that Enbrel’s pediatric labeling did not accurately reflect the existing data.
Ultimately, FDA used the biosimilar’s labeling to advance the state of the knowledge, even if only temporarily, about etanercept use...







